The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years ...

The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain.

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The U.S. Food and Drug Administration (FDA) has approved a new pain pill called Journavx, designed to mitigate the risks of addiction and overdose associated with opioid medications like Vicodin and ...

The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.